|
|
Blood, 1 October 2009, Vol. 114, No. 14, pp. 2858-2859.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Comment on Yi et al, page 3101
T cells helping GVHD: take-away lessons
Daniel Fowler
NATIONAL INSTITUTES OF HEALTH
Using double cytokine knockout donor CD4 cells, in this issue of Blood, Yi and colleagues help clarify the complex role of IFN- and the tissue specificity of Th1, Th17, and Th2 subsets in murine GVHD.1
Murine models investigating the role of functionally defined donor T-cell subsets in graft-versus-host disease (GVHD) have in general taken 1 of 2 approaches: either adding back purified or ex vivo expanded donor T-cells or using donor T-cells deficient in a subset-related cytokine. In the article by Yi et al, this latter "take-away" approach is taken to a higher state by use of double knockout T cells, specifically IFN-–/–IL-4–/– and IFN-–/–IL-17–/– CD4+ T cells consequently deficient in Th1/Th2 function and Th1/Th17 function, respectively. The investigators conclude that wild-type T cells by default develop into Th1 cells that primarily mediate gut and liver GVHD. By comparison, Th1/Th2 takeaway predisposes to Th17-cell outgrowth, which manifests primarily as skin GVHD. Association of Th17 cells with skin GVHD has been reported,2 but the current work reserves lung GVHD for Th2-cell pathology, which is generated after Th1/Th17 takeaway. As such, the 3 T helper subsets appear to be "reciprocal" or stated otherwise, perhaps opportunistic, whereby the absence of two facilitates predominance of the third. The work is particularly interesting because it quantifies CD4 cell transcription factor expression to account for reciprocity at the single-cell level. For example, IFN–/– CD4 cell infusion led to an approximately 10-fold increase in Th2 cells that expressed GATA-3 and an approximately 20-fold increase in Th17 cells that expressed RORt. To further test this reciprocity model, it would be interesting to know whether simultaneous deficiency of IL-4 and IL-17 would further increase Th1 cells expressing t-bet and thereby exacerbate Th1-mediated gut and liver GVHD.
Although the article understandably focuses on the reciprocal balance of Th1, Th2, and Th17 cells, a fourth donor CD4+ T-cell subset, regulatory T cells, which are known to down-regulate GVHD,3,4 were not taken away or added back to this already dizzying array of immune interventions. Presumably, based on the literature,5,6 regulatory T cells would be capable of suppressing each of the Th1-, Th2-, and Th17-mediated GVHD pathologies described. The experiments also focused on CD4-mediated GVHD. Because others have described a differential role of Th17 cells in GVHD models that were CD4-mediated or both CD4- and CD8-mediated,7 further research should address reciprocal Th1/Th2/Th17 effects in the conventional CD8 cell replete transplantation context.
The experiments in particular shed light onto the biology of Th2-mediated lung GVHD that was uncovered with Th1/Th17 deficiency. The mechanistic aspects were relatively classic for a Th2 immune response because recipients of IFN-–/–IL-17–/– CD4+ T cells treated with anti–IL-4 or genetically deficient in IL-4 receptor signaling had reduced lung GVHD. Interestingly, the pathogenic Th2 cells that arose in this model secreted TNF- in preference to IL-10 at a 10:1 ratio. Such Th2 cells likely represent a different brand than the population of Th2 cells that we found to down-regulate established GVHD in part via an IL-10–dependent mechanism.8 On the first level, the results are significant because they indicate that the dreaded complication of lung GVHD may emanate from a relative deficiency of T cells generally viewed as proinflammatory, the Th1 and Th17 subsets. Indeed, it would be interesting to know whether Th1-cell adoptive transfer might somewhat paradoxically ameliorate this type of lung GVHD. Toward this point, the authors demonstrated that posttransplantation cytokine therapy with IFN- improved Th2-mediated lung GVHD. Furthermore, it was found that IFN- therapy operated by up-regulating host tissue expression of the counterregulatory molecule, programmed death ligand-1. In sum, in this model, Th2-mediated lung GVHD occurred as a result of Th1- and Th17-cell deficiency, was dependent on donor IL-4 and either IL-4 or IL-13 signaling on host tissue, and was reversed by IFN- via a host-dependent PD-L1 pathway. These findings are an example of the complicated circuitry of GVHD that can be uncovered by meticulous investigation, thereby identifying cellular and molecular targets for treating GVHD in a tissue-specific manner. Furthermore, these results improve an understanding of the somewhat paradoxical role of IFN- in GVHD9 and speak to the important role of the PD-1/PD-L1 pathway for immune regulation after allogeneic hematopoietic cell transplantation.10
Footnotes
Conflict-of-interest disclosure: The author declares no competing financial interests. 
REFERENCES
- Yi T, Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009;114(14):3101–3112.[Abstract/Free Full Text]
- Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro–differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood. 2009;113(6):1365–1374.[Abstract/Free Full Text]
- Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493–3499.[Abstract/Free Full Text]
- Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144–1150.[CrossRef][Medline]
[Order article via Infotrieve]
- Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 2007;110(10):3804–3813.[Abstract/Free Full Text]
- Lewkowich IP, Herman NS, Schleifer KW, et al. CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med. 2005;202(11):1549–1561.[Abstract/Free Full Text]
- Kappel LW, Goldberg GL, King CG, et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood. 2009;113(4):945–952.[Abstract/Free Full Text]
- Foley JE, Mariotti J, Ryan K, Eckhaus M, Fowler DH. Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. Biol Blood Marrow Transplant. 2008;14(9):959–972.[CrossRef][Medline]
[Order article via Infotrieve]
- Murphy WJ, Welniak LA, Taub DD, et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest. 1998;102(9):1742–1748.[Medline]
[Order article via Infotrieve]
- Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171(3):1272–1277.[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease
- Tangsheng Yi, Ying Chen, Lin Wang, Gong Du, Daniel Huang, Dongchang Zhao, Heather Johnston, James Young, Ivan Todorov, Dale T. Umetsu, Lieping Chen, Yoichiro Iwakura, Fouad Kandeel, Stephen Forman, and Defu Zeng
Blood 2009 114: 3101-3112.
[Abstract]
[Full Text]
[PDF]
|
|
